S&P 500

5.460,48

-0,41%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Cellectis SA (CLLS)
Cellectis SA (CLLS) Notícias

CLLS

Cellectis (CLLS)

Cellectis SA

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:CLLS

1 2 3 4 5 6 7 8 9 10 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
28/06/2024	17:30	GlobeNewswire Inc.	Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024	NASDAQ:CLLS	Cellectis SA
20/06/2024	17:30	GlobeNewswire Inc.	Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing	NASDAQ:CLLS	Cellectis SA
12/06/2024	17:35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
12/06/2024	17:30	GlobeNewswire Inc.	Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications	NASDAQ:CLLS	Cellectis SA
04/06/2024	17:30	GlobeNewswire Inc.	Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia	NASDAQ:CLLS	Cellectis SA
29/05/2024	17:30	GlobeNewswire Inc.	Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024	NASDAQ:CLLS	Cellectis SA
28/05/2024	17:30	GlobeNewswire Inc.	Cellectis Reports Financial Results for First Quarter 2024	NASDAQ:CLLS	Cellectis SA
27/05/2024	17:30	GlobeNewswire Inc.	Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024	NASDAQ:CLLS	Cellectis SA
06/05/2024	03:00	GlobeNewswire Inc.	Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca	NASDAQ:CLLS	Cellectis SA
02/05/2024	17:30	GlobeNewswire Inc.	Cellectis Appoints Arthur Stril as Interim Chief Financial Officer	NASDAQ:CLLS	Cellectis SA
29/04/2024	17:46	GlobeNewswire Inc.	Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023	NASDAQ:CLLS	Cellectis SA
22/04/2024	17:30	GlobeNewswire Inc.	Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	NASDAQ:CLLS	Cellectis SA
10/04/2024	17:30	GlobeNewswire Inc.	Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs	NASDAQ:CLLS	Cellectis SA
08/04/2024	17:30	GlobeNewswire Inc.	Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting	NASDAQ:CLLS	Cellectis SA
16/01/2024	18:30	GlobeNewswire Inc.	Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)	NASDAQ:CLLS	Cellectis SA
22/12/2023	18:30	GlobeNewswire Inc.	Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023	NASDAQ:CLLS	Cellectis SA
17/11/2023	18:30	GlobeNewswire Inc.	Cellectis’ Shareholders Meeting to be Held on December 22, 2023	NASDAQ:CLLS	Cellectis SA
15/11/2023	04:30	GlobeNewswire Inc.	Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca	NASDAQ:CLLS	Cellectis SA
06/11/2023	18:30	GlobeNewswire Inc.	Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023	NASDAQ:CLLS	Cellectis SA
02/11/2023	17:30	GlobeNewswire Inc.	Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting	NASDAQ:CLLS	Cellectis SA
01/11/2023	17:30	GlobeNewswire Inc.	Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023	NASDAQ:CLLS	Cellectis SA
01/11/2023	16:15	AllPennyStocks.com	Biotech Shares Soar After AstraZeneca Stake & Research Collaboration	NASDAQ:CLLS	Cellectis SA
01/11/2023	08:52	Dow Jones News	Cellectis Shares Soar Premarket on AstraZeneca Deal	NASDAQ:CLLS	Cellectis SA
01/11/2023	05:17	Dow Jones News	AstraZeneca to Invest $245 Million in Deal With Cellectis	NASDAQ:CLLS	Cellectis SA
01/11/2023	04:00	GlobeNewswire Inc.	Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca	NASDAQ:CLLS	Cellectis SA
31/10/2023	18:10	Edgar (US Regulatory)	Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]	NASDAQ:CLLS	Cellectis SA
31/10/2023	17:30	GlobeNewswire Inc.	Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting	NASDAQ:CLLS	Cellectis SA
12/10/2023	17:30	GlobeNewswire Inc.	Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)	NASDAQ:CLLS	Cellectis SA
27/09/2023	17:30	GlobeNewswire Inc.	Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting	NASDAQ:CLLS	Cellectis SA
05/09/2023	17:32	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:CLLS	Cellectis SA